111 Capital Initiates $1.74 Million Position in Johnson & Johnson

Key Facts

1111 Capital acquired 8,416 shares of Johnson & Johnson for a total investment of $1.74 million.

2Johnson & Johnson raised its full-year guidance and increased its quarterly dividend following strong financial results.

As institutional investors seek stability and growth within the healthcare sector, 111 Capital has initiated a new position in Johnson & Johnson. The firm acquired 8,416 shares for a total investment of $1.74 million, according to recent filings. This move follows Johnson & Johnson’s decision to raise its full-year financial guidance and increase its quarterly dividend payouts on the back of robust quarterly earnings that surpassed analyst expectations.

This investment underscores the positive sentiment surrounding JNJ, which currently maintains a 'Moderate Buy' consensus rating among analysts, performing steadily alongside peers like Pfizer and Eli Lilly. Historically, the company has a long-standing track record of dividend growth, making it a staple for value-oriented institutional portfolios during market uncertainty. Per market data, institutional inflows into defensive mega-cap stocks have remained resilient throughout the current quarter.

Traders should monitor current price action, with JNJ closing at $147.52 (close June 5, 2026). Looking ahead, market sentiment in the healthcare space may be influenced by Fed Chair Powell’s speech on May 31 and the South Korean Inflation Rate data on June 1, which provides insight into global manufacturing costs. Support levels derived from recent weekly lows remain a key technical focus for retail participants.